VIR · XBRL financial data

Vir Biotechnology financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (VIR's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue	17*	56	3	2	12*	3	1	0	64*	(0)	239	(0)
Revenue from contracts with customers	year only	56	3	2	12*	3	1	0	64*	—	—	—
Cost of revenue	1*	0	0	0	1*	0	0	—	year only	—	0	—
Research and development	112*	100	105	195	106*	119	98	151	88*	109	135	80
Selling, general and administrative	43*	36	30	26	27*	24	22	22	24*	23	30	24
Operating income (loss)	(139)*	(80)	(159)	(231)	(117)*	(140)	(118)	(173)	(48)*	(132)	73	(105)
Interest income	21*	21	19	18	14*	12	11	9	8*	7	9	9
Other income (expense)	(1)*	(0)	(1)	(1)	(1)*	(0)	0	(0)	(0)*	(0)	(0)	(1)
Income tax expense (benefit)	(5)*	0	(2)	0	(0)*	0	0	0	(0)*	0	0	(0)
Net income (loss)	(116)*	(65)	(138)	(214)	(105)*	(121)	(111)	(163)	(43)*	(126)	80	(96)
Earnings per share, basic USD per share	(0.86)*	(0.48)	(1.02)	(1.56)	(0.76)*	(0.88)	(0.80)	(1.17)	(0.31)*	(0.85)	0.48	(0.57)
Earnings per share, diluted USD per share	(0.86)*	(0.48)	(1.02)	(1.56)	(0.76)*	(0.88)	(0.80)	(1.17)	(0.31)*	(0.85)	0.47	(0.57)
Weighted average shares, basic millions of shares	135*	135	136	137	137*	137	138	139	139*	147	168	169
Weighted average shares, diluted millions of shares	135*	135	136	137	137*	137	138	139	139*	147	169	169

Fiscal quarters (VIR's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	242	161	297	168	223	274	211	170	232	274	279	219
Marketable securities	1,271	985	850	741	678	517	388	328	229	196	250	236
Prepaid and other current assets	53	50	41	43	48	42	41	37	45	45	39	48
Total current assets	1,588	1,213	1,206	1,047	1,042	932	736	546	514	523	574	508
Property and equipment, net	96	92	66	65	63	62	61	58	56	53	50	48
Right-of-use asset	71	70	62	61	60	59	65	64	62	61	59	58
Goodwill	17	17	17	17	17	17	17	17	17	17	17	17
Total assets	1,919	1,794	1,670	1,498	1,399	1,308	1,193	1,019	1,003	1,026	1,215	1,112
Accounts payable	6	7	4	7	5	4	12	7	10	5	18	11
Total current liabilities	175	94	96	117	120	137	105	75	93	74	95	81
Lease liability, non-current	112	109	95	93	90	88	93	91	89	87	84	81
Total liabilities	329	247	236	258	248	264	245	223	238	213	232	216
Accumulated deficit	(238)	(303)	(441)	(655)	(760)	(881)	(992)	(1,155)	(1,198)	(1,323)	(1,243)	(1,340)
Total stockholders' equity	1,590	1,547	1,434	1,241	1,150	1,044	947	796	765	813	982	896
Total liabilities and equity	1,919	1,794	1,670	1,498	1,399	1,308	1,193	1,019	1,003	1,026	1,215	1,112
Common shares outstanding (cover page) millions of shares	135	136	137	138	137	138	139	139	140	169	169	171

Fiscal quarters (VIR's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(116)*	(65)	(138)	(214)	(105)*	(121)	(111)	(163)	(43)*	(126)	80	(96)
Stock-based compensation	28*	24	22*	17*	16*	14	12*	11*	11*	12	12*	10*
Depreciation and amortization	4*	5	4*	3*	3*	3	3*	3*	3*	3	3*	3*
Net cash from operating activities	(108)*	(109)	(78)*	(171)*	(88)*	(78)	(120)*	(168)*	(26)*	(132)	123*	(106)*
Purchases of property and equipment	2*	2	1*	2*	2*	2	3*	0*	0*	0	0*	0*
Net cash from investing activities	(105)*	28	212*	119*	141*	127	56*	40*	87*	12	(197)*	45*
Proceeds from issuing common stock	—	—	—	—	—	0	—	—	—	162	—	—
Net cash from financing activities	2*	0	3*	0*	1*	1	2*	0*	1*	163	78*	2*
Net change in cash	(211)*	(81)	137*	(53)*	54*	49	(62)*	(127)*	62*	42	5*	(60)*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Vir Biotechnology	219	(0.2)	(106)*	171.3M	11.8 quarters	Q3 FY26 10-QSep 30, 2026
ImmunityBio	76	51	(66)*	1.1B	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Anavex Life Sciences	118	not reported	(9.1)*	92.7M	13.0 quarters	Q3 FY26 10-QJun 30, 2026
Immunome	218	0	(62)*	113.6M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Anaptysbio	134	27*	(27)*	29.9M	6.2 quarters	Q4 FY26 10-KTJun 30, 2026
Amphastar Pharmaceuticals	205	208	43*	42.7M	—	Q3 FY26 10-QSep 30, 2026
Pacira BioSciences	247	177	50*	40.1M	—	Q3 FY26 10-QSep 30, 2026
Phibro Animal Health	76	387	26	not reported	—	Q1 FY27 10-QSep 30, 2026
uniQure	98	5.2	(48)*	70.1M	2.6 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 11:14 AM ET. The filing on SEC.gov is the record.